InvestorsHub Logo
Followers 12
Posts 3792
Boards Moderated 0
Alias Born 04/30/2004

Re: None

Tuesday, 05/03/2022 11:51:18 AM

Tuesday, May 03, 2022 11:51:18 AM

Post# of 1449
Lineage Cell Therapeutics (LCTX) Received its Third Buy in a Row

Source: TipRanks
After Maxim Group and Noble Financial gave Lineage Cell Therapeutics (NYSE MKT: LCTX) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Joseph Pantginis reiterated a Buy rating on Lineage Cell Therapeutics today and set a price target of $7.00. The company's shares closed last Monday at $1.20, close to its 52-week low of $1.13. According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -28.4% and a 17.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Actinium Pharmaceuticals, and Checkpoint Therapeutics.
https://www.tipranks.com/news/blurbs/lineage-cell-therapeutics-lctx-received-its-third-buy-in-a-row-3?utm_source=advfn.com&utm_medium=referral
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LCTX News